Results 81 to 90 of about 70,452 (325)

Potential Probiotic Lacticaseibacillus paracasei MJM60396 Prevents Hyperuricemia in a Multiple Way by Absorbing Purine, Suppressing Xanthine Oxidase and Regulating Urate Excretion in Mice

Microorganisms, 2022
Hyperuricemia is a metabolic disorder caused by increased uric acid (UA) synthesis or decreased UA excretion. Changes in eating habits have led to an increase in the consumption of purine-rich foods, which is closely related to hyperuricemia.
Youjin Lee, Pia Werlinger, J. Suh, Jinhua Cheng   +3 more
semanticscholar   +1 more source

A Touch Enabled Hemodynamic and Metabolic Monitor

Advanced Science, EarlyView.
This work presents a touch‐based hybrid platform for simultaneous monitoring of vital signs and sweat metabolites. With a simple tri‐finger touch of 4–6 min, users can concurrently get to know their glucose, uric acid, cortisol levels from fingertip sweat, along with blood pressure and heart rate.
Omeed Djassemi, Tamoghna Saha, Ponnusamy Nandhakumar, Muhammad Inam Khan, Hannah Fishman, Sara Earney, Chochanon Moonla, Yuchen Xu, Henry Thai, Sofia Morales‐Fermin, Gyeongho Kim, Rhea Park, Beya Acot, Oscar Wu, Cannon Wurster, An‐Yi Chang, Christopher Cheung, Julia Silberman, Shichao Ding, Joseph Wang   +19 more
wiley   +1 more source

Asymptomatic hyperuricemia: secret relationships, invisible effects and potential complications

Научно-практическая ревматология, 2021
Hyperuricemia is a widespread problem worldwide, the incidence of which is 16-17%. However, the significance of asymptomatic hyperuricemia - hyperuricemia without gout - continues to be discussed.
I. Yu. Golovach, Y. D. Yehudina, S. Kh. Ter-Vartanian   +2 more
doaj   +1 more source

A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease

Frontiers in Endocrinology, 2022
Background and aims Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly emerged term that is suggested to better reflect the pathogenesis of nonalcoholic fatty liver disease (NAFLD); however, the association between hyperuricemia and ...
Chengzhang Yang, Qian-Dong He, Ze‐Dong Chen, Juan-Juan Qin, Fang Lei, Ye Liu, Weifang Liu, Ming-Ming Chen, T. Sun, Qian Zhu, Yonglin Wu, M. Zhuo, Jingjing Cai, W. Mao, Hongliang Li   +14 more
semanticscholar   +1 more source

Hyperuricemia and diabetes mellitus when occurred together have higher risks than alone on all-cause mortality and end-stage renal disease in patients with chronic kidney disease

BMC Nephrology, 2022
Introduction Hyperuricemia and diabetes mellitus (DM) are associated with increased mortality risk in patients with chronic kidney disease (CKD). Here we aimed to evaluate the independent and joint risks of these two conditions on mortality and end stage
Cheng-Hung Li, Chia-Lin Lee, Yu-Cheng Hsieh, Cheng-Hsu Chen, Ming-Ju Wu, Shang-Feng Tsai   +5 more
doaj   +1 more source

Folic acid and zinc improve hyperuricemia by altering the gut microbiota of rats with high-purine diet-induced hyperuricemia

Frontiers in Microbiology, 2022
A high-purine diet can cause hyperuricemia and destroy the microbial composition of the gut microbiota. Both folic acid and zinc significantly reduce uric acid levels and alleviate hyperuricemia.
Xuewei Sun, J. Wen, Baosheng Guan, Jialin Li, Jincheng Luo, Jie Li, Mingyu Wei, Hongbin Qiu   +7 more
semanticscholar   +1 more source

Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China

Arthritis &Rheumatology, Accepted Article.
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun, Yu Wang, Yongjing Cheng, Dongmei Guo, Jiankang Hu, Dongzhou Liu, Zhengnan Gao, Changgui Li, Yibing Lu, Xiaodan Kong, Yu Liu, Zhenyu Jiang, Bin Yi, Hongfeng Zhang, Baijie Xu, Shihao Yu, Rieko Kokan, Kohei Ishikawa, Mikiko Kawakatsu, Zhuoli Zhang   +19 more
wiley   +1 more source

Polymorphisms of the genes ABCG2, SLC22A12 and XDH and their relation with hyperuricemia and hypercholesterolemia in Mexican young adults [version 2; peer review: 2 approved]

F1000Research, 2021
Background: Hyperuricemia is a pathological condition associated with risk factors of cardiovascular disease. In this study, three genetic polymorphisms were genotyped as predisposing factors of hyperuricemia.
Juan Manuel Vargas-Morales, Martha Guevara-Cruz, Celia Aradillas-García, Lilia G. Noriega, Armando Tovar, Jorge Alejandro Alegría-Torres   +5 more
doaj   +1 more source

Prevalence of hyperuricemia and the population attributable fraction of modifiable risk factors: Evidence from a general population cohort in China

Frontiers in Public Health, 2022
Data on updated hyperuricemia prevalence in Beijing-Tianjin-Hebei (BTH) region in China, which is one of the world-class urban agglomerations, is sparse. Overweight/obesity, alcohol consumption, smoking and sedentary behavior are modifiable risk factors (
Huijing He, Pei Guo, Jiangshan He, Jingbo Zhang, Yu-jie Niu, Shuo Chen, F. Guo, Feng Liu, Rong Zhang, Qiang Li, Shitao Ma, Binbin Zhang, L. Pan, G. Shan, Minying Zhang   +14 more
semanticscholar   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source